EUCTR2017-003367-35-PL进行中（未招募）1 期
A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira® in Patients with Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient has signed the Informed Consent Form (ICF) and is able to understand and adhere to the visit schedule and study requirements.
- •2.Patient is male or female, 18 to 75 years of age, inclusive, at time of Screening.
- •3.Patient with moderate-to-severe chronic plaque psoriasis who has involved body surface area (BSA) = 10% (Palm Method), = 12 on the PASI, and static Physicians Global Assessments (sPGA) = 3 (moderate) at Screening and at BL.
- •4.Patient has had stable psoriatic disease for at least 2 months (ie, without significant changes as defined by the Investigator or designee).
- •5.Patient is a candidate for systemic therapy and the patient has a previous failure, inadequate response, intolerance, or contraindication to at least 1 systemic antipsoriatic therapy including, but not limited to, methotrexate, cyclosporine, psoralen plus ultraviolet light A (PUVA), and ultraviolet light B (UVB).
- •6.Patient has a negative QuantiFERON test for tuberculosis (TB) during Screening.
- •Note: Patients with an indeterminate QuantiFERON test are allowed if they have all of the following:
- •No evidence of active TB on chest radiograph within 3 months prior to the first dose of study drug.
- •Documented history of adequate prophylaxis initiation prior to receiving study drug in accordance with local recommendations.
- •No known exposure to active TB after most recent prophylaxis.
- •Asymptomatic at Screening and BL.
- •Investigators should check with the medical monitor before enrolling such subjects.
- •7.Women of childbearing potential (except those who are postmenopausal for more than 2 years or if surgically sterile) must have a negative serum pregnancy test during Screening and negative urine pregnancy test at BL.
- •Sexually active women of childbearing potential must agree to use highly effective contraception (sterilization, hormonal contraception pills or injection or implants, sterilization and abstinence) for the duration of the study and until 6 months after the last dose of the study drug.
- •Male patients must agree to use contraception for the duration of the study and agree not to donate sperm during and for 6 months after the last dose of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1.Patient has prior use of 2 or more biologics for treatment of PsO
- •2.Patient diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, other skin conditions (eg, eczema), or other systemic autoimmune disorder inflammatory disease at the time of the Screening visit that would interfere with evaluations of the effect of the study drug on psoriasis
- •3.Patient has prior use of any of the following medications within specified time periods or will require use during the study:
- •a)Topical medications within 2 weeks of BL (Week 1)
- •b)PUVA phototherapy and/or UVB phototherapy within 4 weeks prior to the BL Visit
- •c)Nonbiologic psoriasis systemic therapies (eg, cyclosporine, methotrexate, and acitretin) within 4 weeks prior to the BL Visit
- •d)Any prior or concomitant or biosimilar adalimumab therapy, either approved or investigational
- •e)Any systemic steroid in the 4 weeks prior to BL. Specified washout periods are as follows:
- •1.Investigational agent(s) within 90 days or 5 half-lives (whichever is longer) before BL (Week 1) (Refer to Table 1 for approved/marketed products)
- •4.Patient has received live or attenuated vaccines during the 4 weeks prior to Randomization or has the intention of receiving a live or attenuated vaccine at any time during the study. Patients who test positive for TB must be treated for 1 month prior to taking part in the study. Investigators should check with the medical monitor before enrolling patients receiving active treatment for TB
- •5.Patient has any concurrent condition which, in the opinion of the Investigator, significantly immunocompromises the patient and/or places the patient at unacceptable risk for receiving an immunomodulatory therapy
- •6.Patient has a planned surgical intervention during the duration of the study except those related to the underlying disease and which, in the opinion of the Investigator, will not put the patient at further risk or hinder the patient’s ability to maintain compliance with study drug and the visit schedule
- •7.Patient has an active and serious infection or history of infections as follows:
- •a)Any active infection
- •1)For which nonsystemic anti-infectives were used within 4 weeks prior to Randomization. Note: Patients receiving topical antibiotics for facial acne do not need to be excluded
- •2)Which required hospitalization or systemic anti-infective within 8 weeks prior to Randomization
- •b)Recurrent or chronic infections or other active infection that, in the opinion of the Investigator or designee, might cause this study to be detrimental to the patient
- •c)Invasive fungal infection or mycobacterial infection
- •d)Opportunistic infections, such as listeriosis, legionellosis, or pneumocystis.
- •8.Patient is positive for human immunodeficiency virus, hepatitis C virus antibody, hepatitis B surface antigen (HBsAg) or hepatitis B core antibody
- •9.Patient has severe progressive or uncontrolled, clinically significant disease that in the judgment of the Investigator renders the patient unsuitable for the study
- •10.Patient has a history of malignancy within 5 years except for adequately treated cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma
- •11.Patient has active neurological disease such as multiple sclerosis, Guillain-Barré syndrome, optic neuritis, transverse myelitis, or history of neurologic symptoms suggestive of central nervous system demyelinating disease
- •12.Patient has moderate-to-sever
研究者
相似试验
进行中（未招募）
1 期
A study comparing the efficacy and safety of BAT2506 and Simponi® in participants with active psoriatic arthritisEUCTR2020-002004-39-CZBio-Thera Solutions, Ltd.700
进行中（未招募）
1 期
A study comparing the efficacy and safety of BAT2506 and Simponi® in participants with active psoriatic arthritisPsoriatic arthritis (PsA)MedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2020-002004-39-BGBio-Thera Solutions, Ltd.700
已完成
3 期
Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) and mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40%JPRN-jRCT2080225274Bayer Yakuhin, Ltd.5,500
进行中（未招募）
不适用
A clinical trial to study the safety and effectiveness of three different strengths (0.03%, 0.1% and 0.3%) bimatoprost solution compared to a solution containing no active ingredient (placebo) and an already licenced product (minoxidil 2%) in the treatment of female pattern hair loss in women.Female pattern hair lossMedDRA version: 14.0Level: LLTClassification code 10016407Term: Female pattern hair thinningSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-000380-27-DEAllergan Ltd.300
进行中（未招募）
1 期
A Study of Benralizumab in Patients with Eosinophilic EsophagitisEosinophilic Esophagitis (EoE)MedDRA version: 20.1Level: LLTClassification code 10064220Term: Eosinophilic esophagitisSystem Organ Class: 100000004856EUCTR2019-002871-32-ESAstraZeneca AB210